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Background:  Metabolomic profiling holds promise for early detection of coronary artery disease and in assessing risk for ischemic events. Heparin 
is frequently administered to treat acute coronary syndromes and during routine cardiac catheterization procedures. Because it stimulates lipolysis, 
it is a potential confounder of metabolomic analyses in these populations.
Methods:  We evaluated the effect of heparin use on peripheral blood metabolic profiles obtained during cardiac catheterization using pre- and 
post-procedure sampling in 20 patients who received heparin and 10 control patients who did not. Using mass spectrometry and conventional 
immunoassays, we profiled 69 metabolites (acylcarnitines, amino acids, non-esterified fatty acids and their oxidation byproducts, and conventional 
lipids) in these samples. The difference between mean metabolite levels before and after the procedure was determined and compared between the 
no heparin and heparin groups.
Results:  Clinical characteristics of the no heparin and heparin groups, indication for cardiac catheterization, procedure performed, and other 
periprocedural variables were similar. The mean changes in pre- and post-procedure beta-hydroxybutyrate (5.43 vs. 63.02 mmol/L; u = 57.59 
mmol/L; p =0 .01), ketones (21.17 vs. 92.93 umol/L; u = 71.76 umol/L; p = 0.01), non-esterified fatty acids (0.37 vs. 1.14 mmol/L; u = 0.78 
mmol/L; p = 0.03), and triglycerides (-9.33 vs. -34.95 mg/dL; u = -25.61 mg/dL; p = 0.008) were significantly different between the no heparin and 
heparin groups, respectively.
Conclusions:  We showed that heparin use induces changes in peripheral blood metabolic profiles obtained during cardiac catheterization 
procedures and created a metabolomic signature associated with heparin administration. The metabolite changes are consistent with the known 
lipolytic effect of heparin. These findings are important to allow accurate assessment in future metabolomic studies in populations exposed to 
heparin.
